blank Quick help
blank Maintenance news

Scheduled maintenance

Regular maintenance outages:
between 05.00 and 05.15 hrs CET (Monday to Sunday).

Other outages
Availability
Register Forum

2022.02.11

More...
blank News flashes

News Flashes

New version of the European Patent Register – SPC proceedings information in the Unitary Patent Register.

2024-07-24

More...
blank Related links

Release notes
European Patent Register Assistant
European Patent Register Resource Book
European Patent Register – pocket guide
FAQ - European Patent Register
FAQ - Register Alert
Federated Register (Flyer)
Global Dossier (Flyer)
Register events
Deep link coverage
Federated Register content
The Patent Information Tour
Fair use charter

Extract from the Register of European Patents

EP About this file: EP2304033

EP2304033 - FUNCTIONALIZED POLYPEPTIDES [Right-click to bookmark this link]
StatusNo opposition filed within time limit
Status updated on  14.07.2017
Database last updated on 09.09.2024
Most recent event   Tooltip06.03.2020Lapse of the patent in a contracting state
New state(s): TR		published on 08.04.2020  [2020/15]
Applicant(s)For all designated states
ESBATech, an Alcon Biomedical Research Unit LLC
Wagistrasse 21
8952 Schlieren / CH
[2016/36]
Former [2011/14]For all designated states
ESBATech, an Alcon Biomedical Research Unit LLC
Wagistrasse 21
8952 Schlieren / CH
Inventor(s)01 / URECH, David
Widmen 8
8634 Hombrechtikon / CH
 [2011/14]
Representative(s)Grünecker Patent- und Rechtsanwälte PartG mbB
Leopoldstraße 4
80802 München / DE
[2016/36]
Former [2012/03]Grünecker, Kinkeldey, Stockmair & Schwanhäusser
Anwaltssozietät
Leopoldstrasse 4
80802 München / DE
Former [2011/14]Molitor, Julia, et al
c/o E.Blum & Co.AG Vorderberg 11
8044 Zürich / CH
Application number, filing date09775731.430.06.2009
[2011/14]
WO2009CH00225
Priority number, dateUS20080076775P30.06.2008         Original published format: US 76775 P
[2011/14]
Filing languageEN
Procedural languageEN
PublicationType: A2 Application without search report
No.:WO2010006454
Date:21.01.2010
Language:EN
[2010/03]
Type: A2 Application without search report 
No.:EP2304033
Date:06.04.2011
Language:EN
The application published by WIPO in one of the EPO official languages on 21.01.2010 takes the place of the publication of the European patent application.
[2011/14]
Type: B1 Patent specification 
No.:EP2304033
Date:07.09.2016
Language:EN
[2016/36]
Search report(s)International search report - published on:EP25.03.2010
ClassificationIPC:C12N15/62, C07K16/00, C07K16/22, C07K16/24, A61K47/48, C12N15/10
[2016/20]
CPC:
C12N15/1037 (EP,KR,US); A61K47/60 (EP,KR,US); A61K47/65 (EP,KR,US);
A61P31/00 (EP); A61P37/00 (EP); C07K16/00 (EP,KR,US);
C07K16/241 (EP,KR,US); C12N15/1062 (EP,KR,US); C07K2317/40 (US);
C07K2317/41 (EP,KR,US); C07K2317/622 (US); C07K2319/31 (EP,KR,US) (-)
Former IPC [2011/14]C12N15/62, C07K16/00, C07K16/22, C07K16/24, A61K47/48
Designated contracting statesAT,   BE,   BG,   CH,   CY,   CZ,   DE,   DK,   EE,   ES,   FI,   FR,   GB,   GR,   HR,   HU,   IE,   IS,   IT,   LI,   LT,   LU,   LV,   MC,   MK,   MT,   NL,   NO,   PL,   PT,   RO,   SE,   SI,   SK,   TR [2016/36]
Former [2011/14]AT,  BE,  BG,  CH,  CY,  CZ,  DE,  DK,  EE,  ES,  FI,  FR,  GB,  GR,  HR,  HU,  IE,  IS,  IT,  LI,  LT,  LU,  LV,  MC,  MK,  MT,  NL,  NO,  PL,  PT,  RO,  SE,  SI,  SK,  TR 
TitleGerman:FUNKTIONALISIERTE POLYPEPTIDE[2011/14]
English:FUNCTIONALIZED POLYPEPTIDES[2011/14]
French:POLYPEPTIDES FONCTIONNALISÉS[2011/14]
Entry into regional phase14.01.2011National basic fee paid 
14.01.2011Designation fee(s) paid 
14.01.2011Examination fee paid 
Examination procedure14.01.2011Examination requested  [2011/14]
21.02.2011Amendment by applicant (claims and/or description)
13.06.2012Despatch of a communication from the examining division (Time limit: M06)
21.11.2012Reply to a communication from the examining division
01.11.2013Despatch of a communication from the examining division (Time limit: M04)
04.11.2013Despatch of a communication from the examining division (Time limit: M04)
10.02.2014Reply to a communication from the examining division
04.02.2015Despatch of a communication from the examining division (Time limit: M04)
15.06.2015Reply to a communication from the examining division
24.05.2016Communication of intention to grant the patent
27.07.2016Fee for grant paid
27.07.2016Fee for publishing/printing paid
27.07.2016Receipt of the translation of the claim(s)
Divisional application(s)EP16187295.7  / EP3130603
The date of the Examining Division's first communication in respect of the earliest application for which a communication has been issued is  13.06.2012
Opposition(s)08.06.2017No opposition filed within time limit [2017/33]
Fees paidRenewal fee
27.06.2011Renewal fee patent year 03
31.03.2012Renewal fee patent year 04
10.06.2013Renewal fee patent year 05
31.03.2014Renewal fee patent year 06
10.06.2015Renewal fee patent year 07
10.06.2016Renewal fee patent year 08
Opt-out from the exclusive  Tooltip
competence of the Unified
Patent Court		 See the Register of the Unified Patent Court for opt-out data
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court.
Licence(s)ID:01 01/exclusive
For:AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Licencee:Cell Medica Switzerland AG
Wagistrasse 27
8952 Schlieren / CH
Date:03.07.2013
[2016/43]
Former [2013/36]ID:01 01/exclusive
For:AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LT LU LV MC MK MT NL NO PL PT RO SE SI SK TR
Licencee:Delenex Therapeutics AG
Wagistrasse 27
8952 Schlieren / CH
Date:03.07.2013
[2016/43]
Lapses during opposition  TooltipHU30.06.2009
AT07.09.2016
BE07.09.2016
CY07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
MC07.09.2016
MK07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SI07.09.2016
SK07.09.2016
TR07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
[2020/15]
Former [2019/51]HU30.06.2009
AT07.09.2016
BE07.09.2016
CY07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
MC07.09.2016
MK07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SI07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2019/46]HU30.06.2009
AT07.09.2016
BE07.09.2016
CY07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
MC07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SI07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2019/31]HU30.06.2009
AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
MC07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SI07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2018/11]AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
MC07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SI07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2017/37]AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SI07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2017/34]AT07.09.2016
BE07.09.2016
CZ07.09.2016
DK07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2017/32]AT07.09.2016
BE07.09.2016
CZ07.09.2016
EE07.09.2016
ES07.09.2016
FI07.09.2016
HR07.09.2016
IT07.09.2016
LT07.09.2016
LV07.09.2016
NL07.09.2016
PL07.09.2016
RO07.09.2016
SE07.09.2016
SK07.09.2016
BG07.12.2016
NO07.12.2016
GR08.12.2016
IS07.01.2017
PT09.01.2017
Former [2017/13]ES07.09.2016
FI07.09.2016
HR07.09.2016
LT07.09.2016
LV07.09.2016
NL07.09.2016
SE07.09.2016
NO07.12.2016
GR08.12.2016
Former [2017/11]ES07.09.2016
FI07.09.2016
HR07.09.2016
LT07.09.2016
SE07.09.2016
NO07.12.2016
GR08.12.2016
Former [2017/10]FI07.09.2016
HR07.09.2016
LT07.09.2016
SE07.09.2016
NO07.12.2016
Former [2017/09]FI07.09.2016
LT07.09.2016
NO07.12.2016
Former [2017/07]LT07.09.2016
Cited inInternational search[Y]US2007202045  (DENNIS MARK S [US]) [Y] 1-19 * abstract *;
 [Y]WO0180899  (CANGENE CORP [CA], et al) [Y] 7,9,12 * page 10, lines 2-5; examples 3,11 *;
 [Y]US7211395  (SATO AARON K [US], et al) [Y] 20,21 * column 17, line 63 - column 22, line 67 *;
 [YP]WO2009000099  (ESBATECH AG [CH], et al) [YP] 1-19 * the whole document *
 [XY]  - VITA CLAUDIO, "Engineering novel proteins by transfer of active sites to natural scaffolds", CURRENT OPINION IN BIOTECHNOLOGY, (1997), vol. 8, no. 4, ISSN 0958-1669, pages 429 - 434, XP002551084 [X] 1,4,5 * abstract * [Y] 2,3,6-21

DOI:   http://dx.doi.org/10.1016/S0958-1669(97)80064-X
 [Y]  - CARTER P J, "POTENT ANTIBODY THERAPEUTICS BY DESIGN", NATURE REVIEWS. IMMUNOLOGY, NATURE PUBLISHING GROUP, GB, (20060407), vol. 6, ISSN 1474-1733, pages 343 - 357, XP007901440 [Y] 1-19 * Page 1, section "Pharmacokinetics" *

DOI:   http://dx.doi.org/10.1038/nri1837
 [YD]  - MUMMERT M E ET AL, "DEVELOPMENT OF A PEPTIDE INHIBITOR OF HYALURONAN-MEDIATED LEUKOCYTE TRAFFICKING", JOURNAL OF EXPERIMENTAL MEDICINE, ROCKEFELLER UNIVERSITY PRESS, JP, (20000918), vol. 192, no. 6, ISSN 0022-1007, pages 769 - 779, XP009081295 [YD] 7,9,12,20,21 * abstract *

DOI:   http://dx.doi.org/10.1084/jem.192.6.769
 [YD]  - SHAUNAK SUNIL ET AL, "Site-specific PEGylation of native disulfide bonds in therapeutic proteins", NATURE CHEMICAL BIOLOGY JUN 2006,, (20060601), vol. 2, no. 6, pages 312 - 313, XP002544349 [YD] 13-15 * the whole document *

DOI:   http://dx.doi.org/10.1038/nchembio786
 [A]  - ZANETTI M ET AL, "EXPRESSION OF CONFORMATIONALLY CONSTRAINED ADHESION PEPTIDE IN AN ANTIBODY CDR LOOP AND INHIBITION OF NATURAL KILLER CELL CYTOTOXIC ACTIVITY BY AN ANTIBODY ANTIGENIZED WITH THE RGD MOTIF", EMBO JOURNAL, OXFORD UNIVERSITY PRESS, SURREY, GB, (19930101), vol. 12, no. 11, ISSN 0261-4189, pages 4375 - 4384, XP001194410 [A] 1-6,8-19 * abstract *
The EPO accepts no responsibility for the accuracy of data originating from other authorities; in particular, it does not guarantee that it is complete, up to date or fit for specific purposes.